Dow Jones

51 712,71

0,29%

DAX

Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.

Accueil
Investir
Actions
Etats-Unis
NASDAQ
bioAffinity Technologies Inc (BIAF)
bioAffinity Technologies Inc (BIAF) Actualités

bioAffinity Technologies Inc (BIAF)

0,81

-0,0272

(-3,25%)

Fermé 23 Juin 10:00PM

0,8299

0,0199

(2,46%)

Après les heures de négociation: 1:48AM

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

bioAffinity Technologies Reports Positive Preclinical Findings Showing Proprietary Gene Silencing Technology Is Selectively Cytotoxic to Squamous Skin Cancer Cells Without Harming Healthy Cells

Research suggests a potential topical treatment for common skin cancers, squamous cell and basal cell carcinoma Findings will be presented at...

bioAffinity Technologies Announces Closing of $3.2 Million Offering

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW),a biotechnology company focused on the need for noninvasive, accurate tests for the detection...

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering

WallachBeth Capital Announces Pricing of bioAffinity Technologies $3.2 Million Offering PR Newswire JERSEY...

bioAffinity Technologies Announces Pricing of $3.2 Million Offering

bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive, accurate tests for the...

bioAffinity Technologies Announces Program to Advance Veteran Lung Health: Philips, bioAffinity Technologies and 4DMedical Highlight New Approaches to Lung Health Screening for U.S. Veterans

Expert panel will share real-world case studies to demonstrate how mobile CT screening, noninvasive CyPath® Lung testing, and comprehensive...

Multidisciplinary Physician Panel to Share Real-World Benefits of bioAffinity Technologies’ Noninvasive CyPath Lung Cancer Test in Upcoming Society for Advanced Bronchoscopy Webinar

Interventional pulmonologist, medical oncologist and thoracic surgeon will discuss how CyPath® Lung results have made a critical difference in...

bioAffinity Technologies Announces Notification of Mexico Patent Allowance Covering Novel Lung Cancer Detection Methods Using CyPath® Lung Technology

Strong intellectual property portfolio helps build shareholder value Patent strategy protects CyPath® Lung’s flow cytometry-driven diagnostic...

bioAffinity Technologies Reports Record Monthly CyPath® Lung Unit Sales and Significant Year-Over-Year Growth in April 2026

CyPath® Lung unit sales in April increased nearly 300% compared to April 2025 Increasing unit sales for CyPath® Lung continues first quarter 2026...

bioAffinity Technologies Reports First Quarter 2026 Results and Expanding Adoption and Clinical Usage of CyPath® Lung

CyPath® Lung cancer diagnostic unit sales rise 146% year-over-year Growth expected to accelerate throughout 2026 as planned commercial...

bioAffinity Technologies Launches New Study To Expand Use of CyPath® Lung Technology for Asthma and COPD Diagnosis and Treatment

Collaboration with nation’s largest military medical center focuses on bioAffinity Technologies’ pipeline of solutions to address debilitating...

New Case Study: bioAffinity Technologies’ CyPath® Lung Diagnostic Supports Physician’s Assessment, Prompts Follow-Up Imaging and Defers Unnecessary Biopsy

Standard-of-care imaging and risk models indicated cancer after lung screening revealed 30-millimeter pulmonary nodule CyPath® Lung test affirmed...

bioAffinity Technologies’ CyPath® Lung to Be Featured at Cleveland Clinic Annual “Advances in Early Lung Cancer Detection” Symposium April 16

Invitation-only conference focuses on the evolving landscape of lung cancer risk and early detection when the disease is most treatable...

bioAffinity Technologies’ CyPath® Lung Test Unit Sales Surged 146% Year-Over-Year in Q1 2026

Noninvasive diagnostic continues to gain traction in the current and expanding U.S. addressable market of $3.58 billion for pulmonary nodule...

bioAffinity Technologies to Host Live Virtual Physician Roundtable on Integrating CyPath® Lung into Pulmonary Practice

Panel of leading pulmonologists will share real-world patient cases and benefits of clinical use of the noninvasive CyPath® Lung diagnostic test...

New Case Study: bioAffinity Technologies’ CyPath® Lung Provides Actionable Results and Helps Patient Avoid Costly, Invasive Procedures

CyPath® Lung improves diagnostic clarity in patients with multiple lung nodules In this case study, CyPath® Lung “Unlikely Malignancy” result...

Forums

Afficher les forums

Aucune Discussion Trouvée

Ajouter une Discussion

NASDAQ

BIAF

bioAffinity Technologies

LSE

0L85

Sorrento Therapeutics

NASDAQ

ABLCKXX

Bank of Montreal Capped ...

Agf Elements Balanced Po...

iNAV db xtrackers MSCI E...

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

Vous avez déjà un compte? Connexion

Vous n'avez pas de compte ? Inscription

En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.

Donnée du Marché

Actualité

Outils

Donnée du Marché

Discover

Hot Features

Follow Feed

Flux des Options

Moniteur

bioAffinity Technologies Inc (BIAF)

Outils de qualité professionnelle, pour des investisseurs individuels.